A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.

Elio P Monsour; Joshua Pothen; Rama Balaraman

doi:10.7759/CUREUS.5824

A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.

Elio P Monsour
, Joshua Pothen
, Rama Balaraman

University of Central Florida
Internal Medicine, General Medical Education, Ocala Regional Medical Center, Ocala, USA.
Hematology and Oncology, Florida Cancer Affiliates / Ocala Oncology, Ocala, USA.

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cureus
Volume	11
Issue number	10
DOIs	https://doi.org/10.7759/CUREUS.5824
State	Published - Oct 2 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Dermatology

Access to Document

10.7759/CUREUS.5824License: Unspecified

Cite this

@article{aaab9b1aafed4ee6af389e25d6e6682d,

title = "A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.",

author = "Monsour, \{Elio P\} and Joshua Pothen and Rama Balaraman",

note = "While immune checkpoint inhibitors have been groundbreaking for cancer treatment, there are many reported cases of patients undergoing immunotherapy who have discontinued or temporarily interrupted treatment due to the development of autoimmune-related adverse effects. Here, we present a 63-year-old ...",

year = "2019",

month = oct,

day = "2",

doi = "10.7759/CUREUS.5824",

language = "American English",

volume = "11",

journal = "Cureus",

publisher = "Springer",

number = "10",

}

TY - JOUR

T1 - A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.

AU - Monsour, Elio P

AU - Pothen, Joshua

AU - Balaraman, Rama

N1 - While immune checkpoint inhibitors have been groundbreaking for cancer treatment, there are many reported cases of patients undergoing immunotherapy who have discontinued or temporarily interrupted treatment due to the development of autoimmune-related adverse effects. Here, we present a 63-year-old ...

PY - 2019/10/2

Y1 - 2019/10/2

UR - https://pubmed.ncbi.nlm.nih.gov/31754559/

U2 - 10.7759/CUREUS.5824

DO - 10.7759/CUREUS.5824

M3 - Article

VL - 11

JO - Cureus

JF - Cureus

IS - 10

ER -

A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report.

Disciplines

Access to Document

Other files and links

Cite this